Xenogesis & Sygnature Hosted Meeting

ApconiX enjoyed a double-billing at the recent ‘Predictive Toxicology in Discovery DMPK’ meeting hosted by Sygnature Discovery and Xenogesis in Nottingham.  Ruth Roberts kicked off the event with the keynote address entitled Roberts Derisking early drug projects Shortened Version March 2018’ (click the title for pdf).  Mike Morton addressed the conference later on in the day with a talk on ‘The Changing Face of Cardiovascular Safety Testing’.  There was much discussion with a highly engaged audience on new challenges and successful strategies to identify and progress those projects with the highest probability of success.  The key is to generate data early, while we still have choices in target and chemistry!

By |2018-06-06T15:26:57+00:00March 23rd, 2018|Events|Comments Off on Xenogesis & Sygnature Hosted Meeting

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.